Due to the significant morbidity and mortality associated with CRPC progression and the crucial role of oxidative stress and NF-κB, it is imperative that this potent Nrf2-activating agent be initiated in a clinical trial to document its safety and efficacy in PCa patients undergoing hormone deprivation. This evidence concerns the gene NFKB1 and posterior cortical atrophy.